ABCC1 polymorphism Arg723Gln (2168G>A) is associated with lung cancer susceptibility in a Chinese population

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 9, 2011, Pages 632-637

  Yin, Ji Ye ^a   Han, Li Fang ^a   Huang, Qiong ^b   Xu, Xiao Jing ^a   Zhou, Hong Hao ^a   Liu, Zhao Qian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

ABCC1; Drug response; Genetic polymorphism; Lung cancer; Multidrug resistance; Multidrug resistance associated protein 1

Indexed keywords

ARGININE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GENOMIC DNA; GLUTAMINE; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CHINESE; CONTROLLED STUDY; DNA EXTRACTION; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; WILD TYPE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 80052078323     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05571.x     Document Type: Article

References (32)

1. Cole SP, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-4.
2. Yang Y, Liu Y, Dong Z et al. Regulation of function by dimerization through the amino-terminal membrane-spanning domain of human ABCC1/MRP1. J. Biol. Chem. 2007; 282: 8821-30.
3. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003; 22: 7537-52.
4. Saito S, Iida A, Sekine A et al. Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR. J. Hum. Genet. 2002; 47: 147-71.
5. Conseil G, Deeley RG, Cole SP. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet. Genomics 2005; 15: 523-33.
6. 2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry 2003; 42: 5214-24.
7. Conrad S, Kauffmann HM, Ito K et al. A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 2002; 12: 321-30.
8. Yin JY, Huang Q, Yang Y et al. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet. Genomics 2009; 19: 206-16.
9. Innocenti F, Kroetz DL, Schuetz E et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol. 2009; 27: 2604-14.
10. Conrad S, Kauffmann HM, Ito K, Deeley RG, Cole SP, Schrenk D. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J. Hum. Genet. 2001; 46: 656-63.
11. Wojnowski L, Kulle B, Schirmer M et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112: 3754-62.
12. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 2000; 92: 205-16.
13. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5: 649-55.
14. Letourneau IJ, Deeley RG, Cole SP. Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet. Genomics 2005; 15: 647-57.
15. Tantisira KG, Lima J, Sylvia J, Klanderman B, Weiss ST. 5-Lipoxygenase pharmacogenetics in asthma: Overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet. Genomics 2009; 19: 244-7.
16. Lima JJ, Zhang S, Grant A et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am. J. Respir. Crit. Care Med. 2006; 173: 379-85.
17. Siedlinski M, Boezen HM, Boer JM, Smit HA, Postma DS. ABCC1 polymorphisms contribute to level and decline of lung function in two population-based cohorts. Pharmacogenet. Genomics 2009; 19: 675-84.
18. Wang HJ, Jin GF, Wang HF et al. Genetic susceptibility of lung cancer associated with common variants in the 3' untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export. Cancer 2009; 115: 595-607.
19. Brechot JM, Hurbain I, Fajac A, Daty N, Bernaudin JF. Different pattern of MRP localization in ciliated and basal cells from human bronchial epithelium. J. Histochem. Cytochem. 1998; 46: 513-7.
20. Wijnholds J, Scheffer GL, van der Valk M et al. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J. Exp. Med. 1998; 188: 797-808.
21. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: Correlation of protein levels with drug response and messenger RNA levels. Clin. Cancer Res. 2001; 7: 1798-804.
22. Giaccone G, van Ark-Otte J, Rubio GJ et al. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. Int. J. Cancer 1996; 66: 760-7.
23. Berger W, Elbling L, Hauptmann E, Micksche M. Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int. J. Cancer 1997; 73: 84-93.
24. Triller N, Korosec P, Kern I, Kosnik M, Debeljak A. Multidrug resistance in small cell lung cancer. Expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 2006; 54: 235-40.
25. Yeh JJ, Hsu NY, Hsu WH, Tsai CH, Lin CC, Liang JA. Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung 2005; 183: 177-83.
26. Warren RB, Smith RL, Campalani E et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J. Invest. Dermatol. 2008; 128: 1925-9.
27. Young LC, Campling BG, Voskoglou-Nomikos T, Cole SP, Deeley RG, Gerlach JH. Expression of multidrug resistance protein-related genes in lung cancer: Correlation with drug response. Clin. Cancer Res. 1999; 5: 673-80.
28. Ota E, Abe Y, Oshika Y et al. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br. J. Cancer 1995; 72: 550-4.
29. Li J, Li ZN, Yu LC et al. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer 2009; 69: 116-22.
30. Campling BG, Young LC, Baer KA et al. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin. Cancer Res. 1997; 3: 115-22.
31. Li J, Li ZN, Du YJ, Li XQ, Bao QL, Chen P. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: Correlation with response to chemotherapy and survival. Clin. Lung Cancer 2009; 10: 414-21.
32. Li XQ, Li J, Shi SB, Chen P, Yu LC, Bao QL. Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. Int. J. Biol. Markers 2009; 24: 230-7.